603567.SH
珍宝岛
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 5.32
−5.67%Aug 28, 2026, 11:57 UTC
Zhenbaodao's independent directors issued opinions on the Shanghai Stock Exchange's 2025 annual report inquiry letter, disclosing that the controlling shareholder had non-operationally occupied company funds of 233 million yuan (already disclosed) and an additional 66.0236 million yuan in 2022 through Heilongjiang Jinjiu Pharmaceutical Co., Ltd., all of which have been fully repaid.
Source:Aug 28, 2026, 11:53 UTC
Zhenbaodao announced its first-half 2026 results, reporting a net loss of 271 million yuan, compared with a loss of 78.29 million yuan in the same period of 2025.
Source:Jul 8, 2026, 12:39 UTC
Zhenbaodao received a letter of inquiry from the Shanghai Stock Exchange regarding its annual report and has responded, with multiple issues still under investigation.
Source:Jul 6, 2026, 08:21 UTC
Zhenbao Island's controlling shareholder Chuangda Group applied to extend the pledge of 132.49 million shares, originally due in July 2026.
Source: